|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,972.50 GBX | +1.15% |
|
+2.65% | +8.11% |
| 06-17 | GSK says US FDA approves urinary tract infection treatment Utebzi | AN |
| 06-17 | GSK plc Receives US FDA Approval for Oral Antibiotic Tebipenem for Complicated Urinary Tract Infections | CI |
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GSK PLC | Other Pharmaceuticals | +1.15% | +2.65% | +8.11% | +33.28% | +9.93% | 104B |
- Stock Market
- Stocks
- GSK Stock
- Charts GSK plc
- Relative Strength Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















